Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [1]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, leading to a stock price drop from $11.40 to $7.64 per share [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from October 9, 2024, to July 10, 2025, are encouraged to register for the class action, with a deadline of September 15, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, inclusive. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New Y ...

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) from the FDA for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 15, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors about the viability of its lead product candidate, deramiocel, during a specific period [1][2]. Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the U.S. [1]. Allegations - The lawsuit claims that during the class period, Capricor misled investors regarding the effectiveness of deramiocel for treating cardiomyopathy associated with DMD, creating a false impression of its approval prospects while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - The complaint highlights that Capricor's misleading statements led to shareholders purchasing securities at artificially inflated prices [2]. Recent Developments - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, which denied its Biologics License Application, citing insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following the announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its regulatory status with the FDA [3][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor and its executives made false and misleading statements regarding the drug deramiocel, particularly concerning its ability to obtain a Biologics License Application (BLA) from the FDA [5]. - The allegations include concealing adverse facts about the four-year safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel [5]. Group 3: Regulatory Developments - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [6]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [7].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly making false and misleading statements regarding its drug candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [1][2]. Summary by Relevant Sections Class Action Details - The lawsuit claims that Capricor misrepresented the progress of its deramiocel drug candidate towards FDA approval, despite being aware of negative data from its Phase 2 HOPE-2 trial [2]. - The deadline for shareholders to join the class action is September 15, 2025 [2]. Shareholder Participation - Shareholders who purchased shares of CAPR during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3]. - Registered shareholders will receive updates through a portfolio monitoring software at no cost [3]. Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy [1][3]. Summary by Sections Class Period and Allegations - The class period for the potential lawsuit is from October 9, 2024, to July 10, 2025 [3]. - Allegations include that Capricor provided investors with misleading information about deramiocel's Biologics License Application (BLA) and concealed adverse facts regarding its Phase 2 HOPE-2 trial safety and efficacy data [3]. FDA Response and Stock Impact - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following this announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its FDA approval process [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor and its executives made false and misleading statements regarding the efficacy and safety data of deramiocel, particularly in relation to its Phase 2 HOPE-2 trial [4]. - Capricor received a Complete Response Letter (CRL) from the FDA on July 11, 2025, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [5]. Group 3: Stock Price Impact - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [6].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]